Summary
Background: Tuberculosis (TB) remains underdiagnosed in many high-burden countries due to high costs and limited availability of rapid molecular tests. Globally, only half of people with TB receive a molecular test as their initial diagnostic test. Pooled testing combines sputum samples from multiple individuals into a single molecular assay, offering cost savings by optimising existing resources, particularly in resource-constrained health systems. Although diagnostic performance has been demonstrated and was reviewed by the WHO Guideline Development Group in November 2025, evidence on real-world feasibility and acceptability for people with TB and healthcare providers remains limited.